US/UK/Canada

Share

Contacts

  • Brede Ellingsæter

    Chief Financial Officer


    Karenlyst Alle 9C, 0278 Oslo, Norway
    +47 47238440
    +47 47238440
    http://www.thormedical.no
    • Pick a time period -
    Tags ( Active)

    Nordic Nanovector – Appointment of Alf Bjørseth as CEO

    Reference is made to the stock exchange announcement made earlier today by Nordic Nanovector ASA ("Nordic Nanovector" or the "Company"), where the Company announced, among other things, that the annual general meeting had elected new board members to the board of directors, including electing former interim CFO & CEO Ludvik Sandnes as new chairman.  Against this background, the board of directors of Nordic Nanovector has today appointed Mr. Alf Bjørnseth as new chief executive officer of Nordic Nanovector. The appointment will be effective as of today. Under Mr. Bjørnseth's employment

    Nordic Nanovector – Completion of annual general meeting

    Reference is made to the stock exchange announcement made by Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") on 6 June 2023 regarding the Company's acquisition of Thor Medical AS (the "Transaction"), with approval of the Transaction from the Company's annual general meeting (the "AGM") as one of the closing conditions.   Please find attached the minutes from the AGM. All items on the agenda were approved by the AGM, including the agenda items relating to the Transaction.   The Transaction is expected to be consummated on or around 3 July 2023.     About

    Nordic Nanovector – Notice of Annual General Meeting on 28 June 2023

    Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 June 2023, at 14:00 hours CEST at Advokatfirmaet CLP, Sommerrogata 13-15, 0255 Oslo. The full notice is attached. The notice and the documents to which it refers are also available on  www.nordicnanovector.com. Shareholders wishing to attend the Annual General Meeting, in person or by proxy, must complete and return the attendance form or power of attorney form attached to the notice to Nordea Bank Abp, Issuer Service, Postboks 1166 Sentrum, N-0107 Oslo, or by e-

    Nordic Nanovector announces agreement to acquire Thor Medical, an emerging producer of alpha-emitters for radiopharmaceuticals to treat cancer

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. · Gives Nordic Nanovector access to highly promising new technology that enables the development and production of radionuclides for radioimmunoconjugate-based approaches to cancer treatment, a rapidly growing global market   · The combined company is expected to have funding through 2025. · Following the acquisition, the new Board of the combined company will

    Nordic Nanovector Publishes Data from the PARADIGME Phase 2 Clinical Trials with Betalutin® on European Clinical Trials Database

    Oslo, Norway,18 April 2023 Nordic Nanovector ASA (OSE: NANOV) (“Nordic Nanovector” or the “Company”) announces that full results from its Phase 2 clinical trials of Betalutin® (177Lu lilotomab satetraxetan) in resistant/refractory (R/R) indolent non-Hodgkin’s lymphoma (NHL) have been published at EudraCT, the European Union Drug Regulating Authorities Clinical Trials Database (the database for all interventional clinical trials on medicinal products submitted to the National Competent Authorities (NCAs) of the European Union). The data from the Phase 1b/2a LYMRIT 37-01 and the Phase 2b

    NORDIC NANOVECTOR – ANNUAL GENERAL MEETING POSTPONED

    Oslo, Norway, 30 March 2023 The Board of Directors of Nordic Nanovector ASA has decided to postpone the upcoming Annual General Meeting (AGM), which was originally scheduled for 26 April. According to Oslo Børs regulations, the Company must hold its AGM before [date]. A new date for the AGM will be announced as soon as possible. Meanwhile, the Company continues to work with potential strategic transactions or partnership that will deliver value for all stakeholders, and will come back with more information in due course.   For further information, please contact: IR enquiries

    NORDIC NANOVECTOR – ANNUAL AND REMUNERATION REPORTS APPROVED

    Oslo, Norway, 23 March 2023 On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2022. The Company's 2022 Annual Report and ESEF file are attached.  The reports are also available on Nordic Nanovector ASA's website: www.nordicnanovector.com For further information, please contact: IR enquiries Ludvik Sandnes, Interim CEO & CFOCell: +47 907 43 017Email: ir@nordicnanovector.com Media Enquiries Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)Tel: +44 203 928 6900Email: nordicnanovector@medistrava.com

    Nordic Nanovector ASA Results for the Second Half and Full Year 2022

    Oslo, Norway, 28 February 2023 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") announces its results for the second half and full year 2022. A presentation by Nordic Nanovector's interim CEO & CFO, Ludvik Sandnes will be held in-person today in Oslo and webcast live beginning at 8:30am CET – details below. Jon Magne Asmyr, Chair of the Board, commented:  The Company’s future is still unclear, and since the turn of the year the new Board has prioritised four important tasks: to get a new CEO/CFO in place; to reduce burn rate; to map the potential of the CD37-

    Nordic Nanovector ASA: Invitation to Second Half and Full Year 2022 Results Presentation and Webcast

    Oslo, Norway, 21 February 2023 Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the second half and full year 2022 on Tuesday, 28 February 2023. A presentation by Nordic Nanovector's interim CEO & CFO, Ludvik Sandnes, will be held in-person and webcast live beginning at 8:30am CET. VENUE: ADVOKATFIRMAET CLP DA, Sommerrogata 13, 0255 Oslo Questions can be submitted in advance to ir@nordicnanovector.com The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page

    Nordic Nanovector ASA announces that Ludvik Sandnes has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO)

    Oslo, Norway, 31 January 2023 Nordic Nanovector ASA (“Nordic Nanovector” or the “Company”) announces that Ludvik Sandnes, former Chairperson of Nordic Nanovector, has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO) of the Company as from 1 February 2023. Ludvik Sandnes will no more attend the Oncoinvent Board. Malene Brondberg, current interim CEO and CFO, will transition out of the Company, as previously announced on 9 December 2022. Ludvik Sandnes commented “I have been asked by the board of Nordic Nanovector to become the interim CEO and CFO

    Nordic Nanovector ASA Notes Publication of Letter by Largest Shareholder North Energy

    Oslo, Norway, 16 January 2023 Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") notes the publication of a letter on 10 January 2023 by North Energy ASA, the largest shareholder of the Company holding approximately 16.5% of the outstanding votes and shares in the Company. In the letter, North Energy requests additional financial information to be published to all shareholders in the upcoming Q4 report due on 28 February 2023; and secondly that the Company pre-announce certain key preliminary financial information prior to the Q4 report (no later than 16 January 2023).

    Nordic Nanovector ASA: Extraordinary General Meeting held

    Oslo, Norway, 3 January 2023 An Extraordinary General Meeting (the "EGM") of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was held today on 3 January 2023 in Oslo, Norway. A new Board of Directors consisting of Jon Magne Asmyr (chairperson), Eddie Berglund and Tina Bjørnlund Bønsdorff was elected by the EGM, as well as a new Nomination Committee consisting of Hans Peter Bøhn (chairperson), Jan-Tore Pedersen and Vegard Aavik. The complete minutes of the EGM are attached to this release, and are available on www.nordicnanovector.com. For further information, please contact:

    Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 3 January 2023

    Oslo, Norway, 13 December 2022 Nordic Nanovector ASA's ("Nordic Nanovector" or the "Company") largest shareholder North Energy ASA, that now holds 11,518,448 shares in the Company, has requested that the Board of Directors calls for an Extraordinary General Meeting in accordance with the Norwegian Public Limited Liability Companies Act §5-7 (2). The Board of Directors therefore calls for an Extraordinary General Meeting to be held on 3 January 2023, at 16:00 hours CET at Advokatfirmaet Selmer, Tjuvholmen Allé 1, 0252 Oslo. The full notice with appendices is attached. The notice and

    Nordic Nanovector update following shareholder vote against proposed merger with APIM Therapeutics

    Oslo, Norway, 9 December 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today announces an update following the Extraordinary General Meeting held on 1 December at which the proposed merger transaction with APIM Therapeutics AS (“APIM”) did not obtain a sufficient majority of votes and was therefore voted down. A new Extraordinary General Meeting ("EGM") will be convened by the Board of Directors with an agenda proposed by North Energy. North Energy is currently the largest shareholder of Nordic Nanovector. The current Board of Directors of Nordic

    Nordic Nanovector ASA: Extraordinary General Meeting held

    Oslo, Norway, 1 December 2022 An Extraordinary General Meeting (the "EGM") of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was held today on 1 December 2022 in Oslo, Norway. The matters under item 3, the proposed transaction with APIM Therapeutics AS, did not obtain sufficient majority of votes and was thus voted down. Due to the results under item 3, the EGM did not vote for the matters under item 4, 5, 6 and 7. The complete minutes of the EGM are attached to this release, and are available on www.nordicnanovector.com. For further information, please contact: IR enquiries

    Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics

    Oslo, Norway, 25 November 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") has today launched a new dedicated area on its website (www.nordicnanovector.com) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics (“APIM”). The new area includes a recording of the webcast and Question & Answer session, which was held for interested parties, including shareholders, on 24 November. During the webcast, shareholders were provided with a more-detailed presentation of the proposed merger with APIM and were given the

    Nordic Nanovector: Invitation to webcast regarding proposed merger with APIM Therapeutics

    Oslo, Norway, 23 November 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") will host a webcast, including a question and answers session on Thursday, November 24 at 4.30 P.M. CET. Reference is made to the stock exchange announcement regarding the Company comments on the proposed merger with APIM Therapeutics November 21. A webcast will be held as described below: Participation details In order to listen to the presentation, visit the Company’s website www.nordicnanovector.com and click on the link to “Webcast”, or sign up and access directly via the

    Nordic Nanovector comment on Proposed Merger with APIM Therapeutics

    Oslo, Norway, 21 November 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") desires to share more information with the Company’s shareholders about the proposed merger between the Company and APIM Therapeutics (“APIM”). The Company has scheduled a webcast, including a question and answers session, on Thursday, November 24 at 4.30 CET. Practical details regarding the webcast will be issued in a separate notice. Any questions may be submitted to ir@nordicnanovector.com. The Board of Nordic Nanovector and its advisors reiterates its belief that the merger

    Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 1 December 2022

    Oslo, Norway, 10 November 2022 Reference is made to the stock exchange announcement by Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") on 9 November 2022 announcing that the Company has entered into a merger agreement with all shareholders of APIM Therapeutics AS to combine the companies in an all-stock transaction. Completion of the transaction is dependent on the approval by the General Meeting of the Company. Nordic Nanovector hereby calls for an Extraordinary General Meeting in the Company to be held on 1 December 2022, at 10:00 hours CET at Advokatfirmaet Selmer,

    Nordic Nanovector and APIM Therapeutics Announce Merger Agreement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. · Merger to create a clinical-stage biotechnology company focused on advancing a portfolio of oncology programmes including a Phase 1b/2a clinical study in platinum-sensitive ovarian cancer and a Phase 2 clinical study in sarcoma · Combined company is expected to have funding into 2024 · Companies will host a joint webcast on 10 November 2022 at 10:00 a.m. CET. The

    Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH Annual Meeting

    Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH Annual Meeting Oslo, Norway, 3 November 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") announces the progress it has made in designing and developing a portfolio of novel and potent humanized anti-CD37 monoclonal antibodies with potential for treating B-cell malignancies or B-cell-driven autoimmune disorders. Details of the Company’s progress in engineering this portfolio are included in two

    Nordic Nanovector consolidates Board to conserve resources while it explores strategic options

    Oslo, Norway, 15 September 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today announces that following the decisions to discontinue the PARADIGME study for its lead asset Betalutin[®], restructure the company and appoint Carnegie Investment Bank to explore strategic options three members of the Company’s Board have decided to step down. Solveig Hellebust, Jean Pierre Bizzari and Thomas Ramdahl will step down from the Board with immediate effect. As previously announced in the press release of 18 August 2022 a strategic exercise led by Carnegie has

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe